Latest News about CYBN
Recent news which mentions CYBN
Mind Medicine, Mindset Pharma Among Top Psychedelic Movers Of Today
January 25, 2022
From Benzinga
Psychedelic Stock Gainers And Losers From January 24, 2022
January 24, 2022
From Benzinga
Psychedelic Stock Gainers And Losers From January 21, 2022
January 21, 2022
From Benzinga
Psychedelic Stock Gainers And Losers From January 20, 2022
January 20, 2022
From Benzinga
From Benzinga
Psychedelic Stock Gainers And Losers From January 18, 2022
January 18, 2022
From Benzinga
Psyched: Delix Raises $30M, New Ketamine Study For Alcohol Use Disorder, FDA Approves Ketamine Trial For ALS
January 18, 2022
From Benzinga
Psychedelic Stock Gainers And Losers From January 17, 2022
January 17, 2022
From Benzinga
Psychedelics Biotech Companies Mark New Milestones In Drug Development Pipelines: Field Trip, Cybin and Wesana
January 11, 2022
From Benzinga
Cybin Receives Notice of Allowance from U.S. Patent Office
December 15, 2021
Tickers
CYBN
From Benzinga
Cybin Developing Safer, More Effective Psilocybin Therapies
December 14, 2021
Tickers
CYBN
From Benzinga
Cybin to Fund, Support Psychedelic Clinic at Manhattan Hospital
December 10, 2021
Tickers
CYBN
From Benzinga
Psilera's DMT-Derived Drug Sees Positive Results in Pre-Clinical Study
December 09, 2021
From Benzinga
Cybin Touts Highlights of 'Transformative' Second-Quarter Performance
December 02, 2021
Tickers
CYBN
From Benzinga
Cybin Announces FDA Approvals, Participation in Conference
December 01, 2021
Tickers
CYBN
From Benzinga
Psilocybin Trials For COVID-Related Distress Of Healthcare Professionals Could Validate New Psychotherapy Model
November 30, 2021
Tickers
CYBN
From Benzinga
Cybin Supports Psychedelic Treatment Clinic Through Grant
November 23, 2021
Tickers
CYBN
From Benzinga
NY's Lenox Hill Hospital With Cybin-Awarded Grant Will Provide Psychedelic Therapy To City's Underserved
November 23, 2021
Tickers
CYBN
From Benzinga
Cybin 'One Step Closer' to Creating Best Therapy for Mental Health
November 19, 2021
Tickers
CYBN
From Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 19, 2021
November 19, 2021
From Benzinga
Cybin Reports Q2 Financial Results And Latest News, Including FDA & DEA Research Approvals
November 15, 2021
Tickers
CYBN
From Benzinga
Can The Psychedelics Boom Go Bust? A Conversation With Cybin Chief Clinical Officer Dr. Alex Belser
November 14, 2021
Tickers
CYBN
From Benzinga
Cybin Unveils Data Suggesting Its Novel Psilocybin Analog Is the 'Superior Molecule'
November 11, 2021
Tickers
CYBN
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.